Patents by Inventor Yung-Hung CHANG

Yung-Hung CHANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for preparing elagolix sodium and intermediates thereof
    Patent number: 11339131
    Abstract: The present invention provides improved processes for the preparation of elagolix and intermediates thereof. The intermediate of formula VII is achieved by a coupling reaction of a compound of formula V and a N-benzylidene protected compound of formula IV: The present invention is suitable for a large-scale production, avoiding the use of potential genotoxic substances and can be performed under mild conditions.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: May 24, 2022
    Assignee: ScinoPharm Taiwan, Ltd.
    Inventors: Yung-Hung Chang, Tsung-Yu Hsiao, Yuan-Xiu Liao, Hsin-Chang Tseng
  • PROCESS FOR PREPARING ELAGOLIX SODIUM AND INTERMEDIATES THEREOF
    Publication number: 20210078956
    Abstract: The present invention provides improved processes for the preparation of elagolix and intermediates thereof. The intermediate of formula VII is achieved by a coupling reaction of a compound of formula V and a N-benzylidene protected compound of formula IV: The present invention is suitable for a large-scale production, avoiding the use of potential genotoxic substances and can be performed under mild conditions.
    Type: Application
    Filed: September 17, 2020
    Publication date: March 18, 2021
    Inventors: Yung-Hung Chang, Tsung-Yu Hsiao, Yuan-Xiu Liao, Hsin-Chang Tseng
  • Crystalline form of olaparib and a process for preparing the same
    Patent number: 10703728
    Abstract: In certain aspects, the invention provides a novel crystalline form of olaparib (4-[(3-[(4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl)-4-fluorophenyl]methyl(2H)phthalazin-1-one). In related aspects, the invention provides a processe for preparing the novel crystalline form of olaparib. The process includes forming a solution comprising crude olaparib and an organic solvent; adding the solution to an anti-solvent to form a slurry comprising a precipitate; isolating the precipitate; and drying the precipitate to obtain a crystalline form III of olaparib.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: July 7, 2020
    Assignee: ScinoPharm Taiwan, Ltd.
    Inventors: Wen-Wei Lin, Tsung-Cheng Hu, Yuan-Chang Huang, Yung-Hung Chang, Kuan-Hsun Wang
  • Processes for preparing olaparib
    Patent number: 10100017
    Abstract: Provided herein are novel processes and methods for making 4-[(3-[(4-cyclopropylcarbonyl)piperazin-1-yl]carbonyl)-4-fluorophenyl]methyl(2H)phthalazin-1-one (Olaparib) and intermediates thereof. Olaparib is a poly ADP ribose polymerase (PARP) inhibitor useful in the treatment of cancers. Benefits of the present disclosure include the use of less toxic compounds and improved yields.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: October 16, 2018
    Assignee: SCINOPHARM TAIWAN, LTD.
    Inventors: Tsung-Yu Hsiao, Yung-Hung Chang
  • PROCESSES FOR PREPARING OLAPARIB
    Publication number: 20180057464
    Abstract: Provided herein are novel processes and methods for making 4-[(3-[(4-cyclopropylcarbonyl)piperazin-1-yl]carbonyl)-4-fluorophenyl]methyl(2H)phthalazin-1-one (Olaparib) and intermediates thereof. Olaparib is a poly ADP ribose polymerase (PARP) inhibitor useful in the treatment of cancers. Benefits of the present disclosure include the use of less toxic compounds and improved yields.
    Type: Application
    Filed: August 23, 2017
    Publication date: March 1, 2018
    Inventors: Tsung-Yu HSIAO, Yung-Hung CHANG